Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 9 of 25, showing 5 Applications out of 123 total, starting on record 41, ending on 45

# Protocol No Study Title Investigator(s) & Site(s)

41.

ECCT/22/07/01   GBT021601-021 Study
    A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Berhnards Ragama Ogutu
3. Videlis Nduba
4. Berhnards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county)
 
View

42.

ECCT/22/06/02   Mitapivat - AG348-C-020
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.   
Principal Investigator(s)
1. Lucas Otieno Tina
2. Bernhards Ragama Ogutu
3. Prof Jessie N Githanga
4. Videlis N Nduba
5. Janet N/A Oyieko
6. Allan Godfrey Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Strathmore University Medical Centre (Nairobi City county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
View

43.

ECCT/22/05/03   Anti-malaria MAb in Kenyan chi
    Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya   
Principal Investigator(s)
1. Titus Kwambai
2. Laura Steinhardt
3. Robert A Seder
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Kogelo Health Center (Siaya county)
 
View

44.

ECCT/22/03/06   Sickle Cell Disease
    A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
2. Fredrick Chite Asirwa
3. Bernhards Ogutu
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Research institute (Kisumu county)
3. International Cancer Centre (Uasin Gishu county)
4. CREATES - Strathmore University Medical Centre (Nairobi City county)
 
View

45.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View